Influenza polymerase inhibitor resistance: Assessment of the current state of the art - A report of the isirv Antiviral group

• Published in: Antiviral research Vol. 194; p. 105158
• Main Authors: Ison, Michael G., Hayden, Frederick G., Hay, Alan J., Gubareva, Larisa V., Govorkova, Elena A., Takashita, Emi, McKimm-Breschkin, Jennifer L.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.10.2021
• Subjects: Animals; Antiviral; Antiviral Agents - adverse effects; Antiviral Agents - pharmacology; Antiviral Agents - therapeutic use; Baloxavir; Dibenzothiepins - pharmacology; Drug resistance; Drug Resistance, Viral; Enzyme Inhibitors - pharmacology; Fitness; Humans; Influenza virus; Influenza, Human - drug therapy; Influenza, Human - virology; Knowledge; Morpholines - pharmacology; Neuraminidase - therapeutic use; Oseltamivir - pharmacology; Polymerase inhibitor; Pyridones - pharmacology; SARS-CoV-2 - drug effects; Triazines - pharmacology; Virus Replication - drug effects; Zanamivir - pharmacology; Antiviral; Drug resistance; Influenza virus; Polymerase inhibitor; Baloxavir; Fitness

It is more than 20 years since the neuraminidase inhibitors, oseltamivir and zanamivir were approved for the treatment and prevention of influenza. Guidelines for global surveillance and methods for evaluating resistance were established initially by the Neuraminidase Inhibitor Susceptibility Networ...